Clinical spectrum and ascertainment pathways in pediatric female dystrophinopathy.
Recognizing dystrophinopathy in girls—historically overlooked because it's X-linked—becomes urgent as gene therapies advance and female patients need earlier diagnosis.
This Italian Journal of Pediatrics study characterizes the clinical spectrum and diagnostic pathways of dystrophinopathy in female pediatric patients, a population historically overlooked because DMD/BMD is X-linked and largely affects males; females with skewed X-inactivation can present with a full spectrum including cardiomyopathy, limb-girdle weakness, and cognitive involvement. Earlier recognition of female dystrophinopathy is increasingly urgent as gene therapies (exon skipping, micro-dystrophin AAV) reach clinical trials that may include female participants.
What the study was
- Study design
- observational_cohort
- Population
- Pediatric female patients with dystrophinopathy (DMD/BMD)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Ital J Pediatr
Why it surfaced
Female dystrophinopathy is severely underdiagnosed and underrepresented in clinical trials; the emergence of approved and investigational DMD gene therapies makes early identification critical for trial eligibility; relevant to rare disease watchlist with high unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.